

1626

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184



June 24, 2002

RECEIVED

JUL 08 2002

FILE: IOWA:042USD1
10107932

TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

June 24, 2002
Date

[Signature]
Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

COPY OF PAPERS
ORIGINALLY FILED

RE: SN 09/612,809 "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" – By Val C. Sheffield

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Supplemental Amendment and Request for Reconsideration Under 37 C.F.R. §1.111; and
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Commissioner for Patents

June 24, 2002

Page 2

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107932/SLH.

Respectfully submitted,



Steven L. Highlander

Reg. No. 37,642

SLH/cpj

Encl.: